Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Genmab A/S
  6. Summary
    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
06/18/2021 06/21/2021 06/22/2021 06/23/2021 06/24/2021 Date
2722(c) 2692(c) 2698(c) 2615(c) 2620 Last
266 244 141 907 138 445 141 666 171 919 Volume
-0.18% -1.10% +0.22% -3.08% +0.19% Change
More quotes
Estimated financial data (e)
Sales 2021 7 668 M 1 230 M 1 230 M
Net income 2021 2 035 M 327 M 327 M
Net cash position 2021 14 830 M 2 380 M 2 380 M
P/E ratio 2021 87,7x
Yield 2021 -
Sales 2022 10 028 M 1 609 M 1 609 M
Net income 2022 3 159 M 507 M 507 M
Net cash position 2022 17 598 M 2 824 M 2 824 M
P/E ratio 2022 56,6x
Yield 2022 -
Capitalization 171 B 27 465 M 27 470 M
EV / Sales 2021 20,4x
EV / Sales 2022 15,3x
Nbr of Employees 871
Free-Float 95,1%
More Financials
Company
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the... 
Sector
Biotechnology & Medical Research
Calendar
08/11 | 11:00amEarnings Release
More about the company
Ratings of Genmab A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about GENMAB A/S
06/23GENMAB A/Sá : Announces that Janssen has Received European Marketing Authorizati..
AQ
06/22GENMAB A/Sá : Grant of Restricted Stock Units and Warrants to Employees in Genma..
PU
06/22GENMAB A/Sá : Grant of Restricted Stock Units and Warrants to Employees in Genma..
AQ
06/22GENMAB A/Sá : Partner Janssen Secures EU Approval for Darzalex SC Combo in Rare ..
MT
06/22Genmab Announces that Janssen has Received European Marketing Authorizations ..
GL
06/22GENMAB A/Sá : - Transactions in connection with share buy-back program
AQ
06/21GENMAB A/Sá : Transactions in connection with share buy-back program (Form 6-K)
PU
06/21GENMAB A/Sá : Transactions in connection with share buy-back program
AQ
06/18PRESS RELEASEá : BioNTech Announces First Patient Dosed in Phase 2 Clinical Tria..
DJ
06/16GENMAB A/Sá : Transactions with shares and linked securities in Genmab A/S made ..
PU
06/15GENMAB A/Sá : Transactions with shares and linked securities in Genmab A/S made ..
PU
06/15GENMAB A/Sá : - Transactions in connection with share buy-back program
AQ
06/14GENMAB A/Sá : Transactions in connection with share buy-back program (Form 6-K)
PU
06/11GENMAB A/Sá : Investor Presentation - June 2021
PU
06/10GENMAB A/Sá : Transactions with shares and linked securities in Genmab A/S made ..
PU
More news
News in other languages on GENMAB A/S
06/18GlobeNewswire/BioNTech gibt Dosierung des ersten Patienten mit fortgeschritte..
06/10GlobeNewswire/Pfizer und BioNTech stellen der -4-
05/28GlobeNewswire/Pfizer und BioNTech erhalten erste -3-
05/21GlobeNewswire/BioNTech veröffentlicht ersten -2-
05/20GlobeNewswire/Pfizer und BioNTech unterzeichnen -3-
More news
Analyst Recommendations on GENMAB A/S
More recommendations
Chart GENMAB A/S
Duration : Period :
Genmab A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 2 620,00 DKK
Average target price 2 425,00 DKK
Spread / Average Target -7,44%
EPS Revisions
Managers and Directors
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Anthony Pagano Chief Financial Officer & Executive Vice President
Deirdre P. Connelly Chairman
Tahamtan Ahmadi Chief Medical Officer & Executive Vice President
Anthony Mancini Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB A/S6.17%27 448
GILEAD SCIENCES, INC.14.40%83 591
WUXI APPTEC CO., LTD.35.04%69 433
BIONTECH SE181.53%55 429
REGENERON PHARMACEUTICALS9.66%54 864
VERTEX PHARMACEUTICALS-20.66%48 542